Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma

Abstract excerpt

BACKGROUND: RAS effector signaling pathways such as PI3K/mTOR and ERK are frequently dysregulated in glioblastoma. While small molecule targeted therapies against these pathways have appeared promising in preclinical studies, they have been disappointing in clinical trials due to toxicity and de novo and adaptive resistance. To identify predictors of glioblastoma sensitivity to dual pathway inhibition with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glioma Diagnosis and Treatment
• Share to Melanoma and MAPK Pathways
• Share to Neurofibromatosis and Schwannoma Cases